StemRIM Inc
TSE:4599
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
326
699
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
StemRIM Inc
Cash & Cash Equivalents
StemRIM Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
StemRIM Inc
TSE:4599
|
Cash & Cash Equivalents
¥8.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Cash & Cash Equivalents
¥16.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
21%
|
CAGR 10-Years
13%
|
|
|
PeptiDream Inc
TSE:4587
|
Cash & Cash Equivalents
¥50.4B
|
CAGR 3-Years
60%
|
CAGR 5-Years
43%
|
CAGR 10-Years
31%
|
|
|
Takara Bio Inc
TSE:4974
|
Cash & Cash Equivalents
¥38B
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
5%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Cash & Cash Equivalents
¥15.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
29%
|
CAGR 10-Years
26%
|
|
|
C
|
Cuorips Inc
TSE:4894
|
Cash & Cash Equivalents
¥5.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
StemRIM Inc
Glance View
StemRIM, Inc. engages in the research and development of regeneration inducing medicine. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 46 full-time employees. The company went IPO on 2019-08-09. The firm is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
See Also
What is StemRIM Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
8.4B
JPY
Based on the financial report for Jul 31, 2024, StemRIM Inc's Cash & Cash Equivalents amounts to 8.4B JPY.
What is StemRIM Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
27%
Over the last year, the Cash & Cash Equivalents growth was -18%. The average annual Cash & Cash Equivalents growth rates for StemRIM Inc have been -6% over the past three years , 27% over the past five years .
You don't have any saved screeners yet
